R. Edwards

发表

Economic analysis of endovascular repair versus surveillance for patients with small abdominal aortic aneurysms.

K. Anstrom, K. Ouriel, E. Eisenstein, 2013, Journal of vascular surgery.

Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials.

Paul L Hess, P. Kudenchuk, D. Mark, 2014, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Outcomes of implantable cardioverter-defibrillator use in patients with comorbidities: results from a combined analysis of 4 randomized clinical trials.

P. Kudenchuk, D. Mark, L. Inoue, 2014, JACC. Heart failure.

A randomized clinical trial of clinical decision support in a rural community health network serving lower income individuals: study design and baseline characteristics.

Janese M. Willis, K. Anstrom, Kensaku Kawamoto, 2009, Studies in health technology and informatics.

SURVIVAL BENEFIT OF THE PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR AMONG OLDER PATIENTS: DOES AGE MATTER? A PATIENT-LEVEL META-ANALYSIS OF 5 CLINICAL TRIALS

Paul L. Hess, P. Kudenchuk, D. Mark, 2014 .

Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy – the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial

K. Anstrom, F. Martinez, I. Noth, 2020, Respiratory Research.

Do patients with a left ventricular ejection fraction between 30% and 35% benefit from a primary prevention implantable cardioverter defibrillator?

P. Kudenchuk, D. Mark, L. Inoue, 2014, International journal of cardiology.

Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials.

Paul L. Hess, Lurdes Y. T. Inoue, P. Kudenchuk, 2013, Heart rhythm.

Feasibility Testing and Validation of the Pulmonary Fibrosis Foundation Patient Registry Occupational and Environmental Exposure Questionnaire (PFF-OEQ)

R. Bascom, M. Gulati, R. Edwards, 2020 .

ong-Term Clinical and Economic Analysis of the ndeavor Zotarolimus-Eluting Stent Versus the ypher Sirolimus-Eluting Stent

K. Anstrom, M. Leon, D. Kandzari, 2022 .

Reduced Length of Hospital Stay in Colorectal Surgery after Implementation of an Enhanced Recovery Protocol

W. White, K. Anstrom, R. Moon, 2014, Anesthesia and analgesia.

Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the cypher sirolimus-eluting stent: 3-year results from the ENDEAVOR III trial (Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Elu

K. Anstrom, M. Leon, L. Mauri, 2009, JACC. Cardiovascular interventions.

The Pulmonary Fibrosis Foundation Patient Registry: Rationale, Design, and Methods.

I. Noth, G. Raghu, J. Stauffer, 2020, Annals of the American Thoracic Society.

The economic returns of pediatric clinical trials of antihypertensive drugs.

R. Califf, H. Grabowski, E. Eisenstein, 2008, American heart journal.

A Randomized Trial of Population-Based Clinical Decision Support to Manage Health and Resource Use for Medicaid Beneficiaries

Kensaku Kawamoto, Janese M. Willis, Jessica Simo, 2013, Journal of Medical Systems.

Survival Benefit of the Primary Prevention Implantable Cardioverter-Defibrillator Among Older Patients: Does Age Matter? An Analysis of Pooled Data From 5 Clinical Trials

P. Kudenchuk, D. Mark, L. Inoue, 2015, Circulation. Cardiovascular quality and outcomes.

Population-Based Clinical Decision Support: A Clinical and Economic Evaluation

Janese M. Willis, Jessica Simo, Kevin J. Anstrom, 2012, MIE.

PCV59 ECONOMIC ANALYSIS OF THE ENDEAVOR DRUG-ELUTING STENT VS. THE DRIVER BARE METAL STENT: RESULTS FROM THE ENDEAVOR II TRIAL

K. Anstrom, D. Mark, E. Eisenstein, 2009 .